Compare · EOCN vs NVO

EOCN vs NVO

Side-by-side comparison of Eocene Ltd. (EOCN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both EOCN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $172.11B, about 94425.9x EOCN ($1.8M).
  • NVO has been more active in the news (9 items in the past 4 weeks vs 4 for EOCN).
  • NVO has more recent analyst coverage (25 ratings vs 0 for EOCN).
MetricEOCNNVO
Company
Eocene Ltd.
Novo Nordisk A/S
Price
-
-
Market cap
$1.8M
$172.11B
1M return
-
-0.41%
1Y return
-
-18.26%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2014
News (4w)
4
9
Recent ratings
0
25
EOCN

Eocene Ltd.

EoCene Ltd. (NASDAQ: EOCN) is a GI-focused medtech and biopharmaceutical company headquartered in Ramat Gan, Israel, dedicated to advancing innovative solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. The Company is building a diversified platform that combines medical devices, therapeutics and enabling technologies to address significant unmet clinical needs and improve patient outcomes. EoCene's wholly owned subsidiary, Colospan Ltd., is a commercial-stage medical device company developing solutions designed to transform postoperative colorectal care. Its flagship product, CG-100, is an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas, offering a less invasive alternative to current surgical practice.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.